PE20070644A1 - Derivados de 9-cloro-15-desoxiprostaglandina como agonistas del receptor de prostaglandina e2 (ep2) y procesos para su preparacion - Google Patents
Derivados de 9-cloro-15-desoxiprostaglandina como agonistas del receptor de prostaglandina e2 (ep2) y procesos para su preparacionInfo
- Publication number
- PE20070644A1 PE20070644A1 PE2006001471A PE2006001471A PE20070644A1 PE 20070644 A1 PE20070644 A1 PE 20070644A1 PE 2006001471 A PE2006001471 A PE 2006001471A PE 2006001471 A PE2006001471 A PE 2006001471A PE 20070644 A1 PE20070644 A1 PE 20070644A1
- Authority
- PE
- Peru
- Prior art keywords
- chloro
- agonists
- tetramethylen
- hydroxy
- alkyl
- Prior art date
Links
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 2
- 229960002986 dinoprostone Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 TETRAHYDROFURANOYL Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 208000021267 infertility disease Diseases 0.000 abstract 1
- IWOPNHXOEGJKIA-PMACEKPBSA-N methyl 7-[(1r,2s)-2-oct-1-enylcyclopentyl]hept-5-enoate Chemical compound CCCCCCC=C[C@H]1CCC[C@@H]1CC=CCCCC(=O)OC IWOPNHXOEGJKIA-PMACEKPBSA-N 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 9-CLOROPROSTAGLANDINA DE FORMULA (I) DONDE R1 ES CH2OH, -COOR2, -CONHR2, ENTRE OTROS, DONDE R2 ES H, ALQUILO(C1-C10) OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALCOXI(C1-C4), ARILO(C3-C10), ENTRE OTROS SUSTITUYENTES, CICLOALQUILO(C3-C10) OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C4), ENTRE OTROS; A ES CIS-CH=CH- O -CH2-CH2-; B ES TRANS-CH=CH- O -CH2-CH2-; W ES ALQUILENO(C2-C6); R4 ES HIDROXI, O-R6 U O-R7, DONDE R6 ES TETRAHIDROPIRANILO, TETRAHIDROFURANOILO, TRIMETILSILILO, ENTRE OTROS; R7 ES ACIDO CARBOXILICO(C1-C15); R5 ES H, ALQUILO(C1-C10) O ALQUENILO(C2-C10); n ES DE 1 A 4. SON COMPUESTOS PREFERIDOS: (5Z,13E)-(9R,11R)-9-CLORO-11-[(2H)-TETRAHIDROPIRAN-2-ILOXI]-17,17-TETRAMETILEN-20-NOR-5,13-PROSTADIENOATO DE METILO, (5Z,13E)-(9R,11R)-9-CLORO-11-HIDROXI-17,17-TETRAMETILEN-20-NOR-5,13-PROSTADIENOATO DE METILO, ACIDO (5Z,13E)-(9R,11R)-9-CLORO-11-HIDROXI-17,17-TETRAMETILEN-20-NOR-5,13-PROSTADIENOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE PROSTAGLANDINA E2 (EP2) SIENDO UTILES PARA EL TRATAMIENTO DE TRANSTORNOS DE FERTILIDAD, ENDOMETRIOSIS, OSTEOPOROSIS, ESCLEROSIS MULTIPLE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05090321A EP1816121B1 (en) | 2005-11-21 | 2005-11-21 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070644A1 true PE20070644A1 (es) | 2007-07-31 |
Family
ID=35744724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001471A PE20070644A1 (es) | 2005-11-21 | 2006-11-20 | Derivados de 9-cloro-15-desoxiprostaglandina como agonistas del receptor de prostaglandina e2 (ep2) y procesos para su preparacion |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1816121B1 (es) |
JP (1) | JP2009516665A (es) |
KR (1) | KR20080068877A (es) |
CN (1) | CN101312946A (es) |
AR (1) | AR057900A1 (es) |
AT (1) | ATE388936T1 (es) |
AU (1) | AU2006314733A1 (es) |
BR (1) | BRPI0618756A2 (es) |
CA (1) | CA2629031A1 (es) |
CR (1) | CR10006A (es) |
DE (1) | DE602005005355T2 (es) |
DK (1) | DK1816121T3 (es) |
DO (1) | DOP2006000257A (es) |
EA (1) | EA200801211A1 (es) |
EC (1) | ECSP088472A (es) |
ES (1) | ES2302122T3 (es) |
GT (1) | GT200800066A (es) |
IL (1) | IL190596A0 (es) |
NO (1) | NO20082838L (es) |
PE (1) | PE20070644A1 (es) |
PL (1) | PL1816121T3 (es) |
PT (1) | PT1816121E (es) |
TW (1) | TW200738611A (es) |
UY (1) | UY29925A1 (es) |
WO (1) | WO2007057232A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183286B2 (en) | 2006-11-16 | 2012-05-22 | Gemmus Pharma Inc. | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4171331A (en) * | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
DE2950027A1 (de) * | 1979-12-10 | 1981-06-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
JP3162668B2 (ja) * | 1997-02-04 | 2001-05-08 | 小野薬品工業株式会社 | ω−シクロアルキル−プロスタグランジンE2誘導体 |
JP2000095755A (ja) * | 1998-07-21 | 2000-04-04 | Ono Pharmaceut Co Ltd | ω―シクロアルキル―プロスタグランジンE1誘導体、その製造方法およびその誘導体を有効成分とする医薬組成物 |
KR20030019628A (ko) * | 2000-07-31 | 2003-03-06 | 오노 야꾸힝 고교 가부시키가이샤 | 프로스타글란딘 유도체를 유효 성분으로 하는 발기부전치료제 |
-
2005
- 2005-11-21 DK DK05090321T patent/DK1816121T3/da active
- 2005-11-21 PL PL05090321T patent/PL1816121T3/pl unknown
- 2005-11-21 AT AT05090321T patent/ATE388936T1/de not_active IP Right Cessation
- 2005-11-21 PT PT05090321T patent/PT1816121E/pt unknown
- 2005-11-21 DE DE602005005355T patent/DE602005005355T2/de active Active
- 2005-11-21 ES ES05090321T patent/ES2302122T3/es active Active
- 2005-11-21 EP EP05090321A patent/EP1816121B1/en not_active Not-in-force
-
2006
- 2006-11-13 TW TW095141974A patent/TW200738611A/zh unknown
- 2006-11-17 AR ARP060105047A patent/AR057900A1/es unknown
- 2006-11-17 UY UY29925A patent/UY29925A1/es not_active Application Discontinuation
- 2006-11-20 KR KR1020087012052A patent/KR20080068877A/ko not_active Application Discontinuation
- 2006-11-20 PE PE2006001471A patent/PE20070644A1/es not_active Application Discontinuation
- 2006-11-20 CN CNA2006800435083A patent/CN101312946A/zh active Pending
- 2006-11-20 JP JP2008540536A patent/JP2009516665A/ja active Pending
- 2006-11-20 WO PCT/EP2006/011378 patent/WO2007057232A1/en active Application Filing
- 2006-11-20 BR BRPI0618756-0A patent/BRPI0618756A2/pt not_active Application Discontinuation
- 2006-11-20 DO DO2006000257A patent/DOP2006000257A/es unknown
- 2006-11-20 EA EA200801211A patent/EA200801211A1/xx unknown
- 2006-11-20 CA CA002629031A patent/CA2629031A1/en not_active Abandoned
- 2006-11-20 AU AU2006314733A patent/AU2006314733A1/en not_active Abandoned
-
2008
- 2008-04-03 IL IL190596A patent/IL190596A0/en unknown
- 2008-05-16 GT GT200800066A patent/GT200800066A/es unknown
- 2008-05-21 CR CR10006A patent/CR10006A/xx not_active Application Discontinuation
- 2008-05-26 EC EC2008008472A patent/ECSP088472A/es unknown
- 2008-06-20 NO NO20082838A patent/NO20082838L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR057900A1 (es) | 2007-12-26 |
DE602005005355D1 (de) | 2008-04-24 |
GT200800066A (es) | 2009-03-12 |
PT1816121E (pt) | 2008-05-28 |
NO20082838L (no) | 2008-06-20 |
ATE388936T1 (de) | 2008-03-15 |
EP1816121B1 (en) | 2008-03-12 |
BRPI0618756A2 (pt) | 2011-09-13 |
AU2006314733A1 (en) | 2007-05-24 |
WO2007057232A1 (en) | 2007-05-24 |
DOP2006000257A (es) | 2007-06-15 |
ES2302122T3 (es) | 2008-07-01 |
IL190596A0 (en) | 2008-11-03 |
EA200801211A1 (ru) | 2008-10-30 |
JP2009516665A (ja) | 2009-04-23 |
KR20080068877A (ko) | 2008-07-24 |
CN101312946A (zh) | 2008-11-26 |
PL1816121T3 (pl) | 2008-08-29 |
UY29925A1 (es) | 2007-06-29 |
TW200738611A (en) | 2007-10-16 |
ECSP088472A (es) | 2008-06-30 |
DE602005005355T2 (de) | 2009-03-26 |
CR10006A (es) | 2008-07-29 |
DK1816121T3 (da) | 2008-06-16 |
EP1816121A1 (en) | 2007-08-08 |
CA2629031A1 (en) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070644A1 (es) | Derivados de 9-cloro-15-desoxiprostaglandina como agonistas del receptor de prostaglandina e2 (ep2) y procesos para su preparacion | |
AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
PE20080970A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos | |
PE20080234A1 (es) | Combinacion antiepileptica que comprende derivados de benzoheteroarilsulfamidas | |
MX2021000375A (es) | Degradadores selectivos del receptor de estrogeno. | |
CO6280476A2 (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
AR050407A1 (es) | Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas | |
NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
EA200970612A1 (ru) | Производные индола в качестве агонистов рецептора s1p1 | |
BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
PE20020872A1 (es) | DERIVADOS DE FENETANOLAMINA COMO AGONISTAS DE LOS ß2-ADRENORECEPTORES | |
CY1117085T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
UY28877A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida y composiciones | |
CO6321273A2 (es) | N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie | |
PE20011184A1 (es) | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa | |
AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
PE20071251A1 (es) | Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
AR061973A1 (es) | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos | |
AR078722A1 (es) | Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
PE20030944A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |